Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuji Murakami

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
JTO Clinical and Research Reports|April 9, 2026
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With <i>EGFR</i> Mutation (West Japan Oncology Group 11719L: ADJUST Study)Ryota Shibaki, Hiroaki Akamatsu, Morihito Okada, et al.
Translational Lung Cancer Research|August 13, 2025
Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasisTetsuya Isaka, Yohei Miyagi, Rika Kasajima, et al.
Journal of Thoracic Disease|August 30, 2019
Efficacy and safety of crizotinib in patients with <i>ROS1</i> rearranged non-small cell lung cancer: a retrospective analysisKen Masuda, Yutaka Fujiwara, Yuki Shinno, et al.
Lung Cancer (Amsterdam, Netherlands)|July 28, 2010
Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical courseShuji Murakami, Tomoyuki Yokose, Haruhiro Saito, et al.
Thoracic Cancer|November 13, 2020
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samplesDaiji Nemoto, Tomoyuki Yokose, Kayoko Katayama, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2023
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitorsHidetomo Himuro, Yoshiro Nakahara, Yuka Igarashi, et al.
Thoracic Cancer|May 3, 2024
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancerNaoko Shigeta, Shuji Murakami, Tomoyuki Yokose, et al.
Frontiers in Immunology|June 1, 2026
Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAPFeifei Wei, Yoshiro Nakahara, Junya Isobe, et al.
Medical Oncology (Northwood, London, England)|March 18, 2020
Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancerHanae Ida, Yasushi Goto, Jun Sato, et al.
Optics Letters|March 2, 2019
Multi-parameter distributed fiber sensing with higher-order optical and acoustic modesJian Fang, Giovanni Milione, Jeffery Stone, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
JTO Clinical and Research Reports|April 9, 2026
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With <i>EGFR</i> Mutation (West Japan Oncology Group 11719L: ADJUST Study)Ryota Shibaki, Hiroaki Akamatsu, Morihito Okada, et al.
Translational Lung Cancer Research|August 13, 2025
Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasisTetsuya Isaka, Yohei Miyagi, Rika Kasajima, et al.
Journal of Thoracic Disease|August 30, 2019
Efficacy and safety of crizotinib in patients with <i>ROS1</i> rearranged non-small cell lung cancer: a retrospective analysisKen Masuda, Yutaka Fujiwara, Yuki Shinno, et al.
Lung Cancer (Amsterdam, Netherlands)|July 28, 2010
Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical courseShuji Murakami, Tomoyuki Yokose, Haruhiro Saito, et al.
Thoracic Cancer|November 13, 2020
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samplesDaiji Nemoto, Tomoyuki Yokose, Kayoko Katayama, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2023
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitorsHidetomo Himuro, Yoshiro Nakahara, Yuka Igarashi, et al.
Thoracic Cancer|May 3, 2024
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancerNaoko Shigeta, Shuji Murakami, Tomoyuki Yokose, et al.
Frontiers in Immunology|June 1, 2026
Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAPFeifei Wei, Yoshiro Nakahara, Junya Isobe, et al.
Medical Oncology (Northwood, London, England)|March 18, 2020
Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancerHanae Ida, Yasushi Goto, Jun Sato, et al.
Optics Letters|March 2, 2019
Multi-parameter distributed fiber sensing with higher-order optical and acoustic modesJian Fang, Giovanni Milione, Jeffery Stone, et al.
Pageof 12